A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Trial Profile

A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Prexasertib (Primary)
  • Indications Nervous system neoplasms; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 24 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 08 Feb 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Jul 2019.
    • 08 Feb 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top